




Figure 1. Boxplot of serum dose of tacrolimus every day




Figure 2. Line of serum concentration in time for every patient in the case series.

<https://doi.org/10.1016/j.aohep.2024.101731>

P-118 METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: INDICATION FOR LIVER TRANSPLANTATION AND OCCURRENCE IN THE POSTOPERATIVE PERIOD

Felipe Ramos Caprini¹,
Guilherme Massote Fontanini²,
Juarez Roberto de Oliveira Vasconcelos²,
Fernanda Fernandes Souza³,
Ajith Kumar Sankarankutty⁴,
Marcia Guimarães Villanova²,
Roberta Chaves Araújo³

¹ Hospital das Clínicas of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil

² Gastroenterology Division, Hospital das Clínicas of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil

³ Professor of the Division of Gastroenterology, Department of Clinical Medicine at Faculty of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil

⁴ Division of Digestive Surgery, Department of Surgery and Anatomy at Faculty of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil

Conflict of interest: No

Introduction and Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most important causes of liver disease worldwide, and it is currently the main indication for liver transplantation.

This study aims to evaluate (1) clinical-epidemiological profile of patients listed for liver transplant due to MASLD-related cirrhosis and mortality on the waiting list; (2) occurrence of allograft steatosis and new post-transplant comorbidities; (3) survival of patients with and without MASLD in the postoperative period.

Patients / Materials and Methods: This retrospective study is based on a review of medical records of patients treated at the Liver Transplant outpatient clinic of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto - University of São Paulo, from 2005 to 2015.

Results and Discussion: Of all patients listed for liver transplant (610), 10% had MASLD-related cirrhosis. Of these, 47.5% were female, with an average age of 56.3 years. These patients had higher MELD values ($P=0.01$), higher rates of metabolic syndrome ($P<0.05$), and waiting list mortality of 42.6%. About transplant patients (264), 58 developed hepatic steatosis post-transplant, 82.8% of these with new steatosis and 17.2% with MASLD recurrence. The development of new comorbidities, such as diabetes and systemic arterial hypertension, was present in 26.2% and 22.5% of transplant recipients. Obesity and hypertension were the variables associated with a greater risk of allograft steatosis. The average survival of patients undergoing surgery was 8.7 years. Individuals transplanted for MASLD had significantly lower survival than those with other causes of cirrhosis ($P=0.05$).

Conclusions: As MASLD is a highly prevalent disease, with different local realities, studies like this can serve as a basis for understanding the local reality and provide important information for developing public health programs.

<https://doi.org/10.1016/j.aohep.2024.101732>

P-119 POST-TRANSPLANT OVERALL AND GRAFT SURVIVAL AFTER LIVER TRANSPLANTATION FOR AUTOIMMUNE HEPATITIS

Ludmila Guedes Resende¹,
Francisco Guilherme Penna Canela¹,
Fernanda Maria Osório Farage¹, Luciana Faria Costa¹,
Daniel Antônio Terra Albuquerque¹,
Artur Miranda M C¹, Guilherme Grossi Cancado¹,
Cláudia Couto Alves¹

¹ UNIVERSIDADE FEDERAL DE MINAS GERAIS, Belo Horizonte, Brasil

Conflict of interest: No

Introduction and Objectives: Autoimmune hepatitis (AIH) represents the cause in 5-6% of the total amount of liver transplant in Brazilian centers. Factors that impact post-transplant outcomes are not well known. Data from the European registry show an overall survival of 79.4% post AIH liver transplant whereas Latin American numbers are scarce. The aim of this study is to evaluate long-term patient and graft survival after liver transplant due to AIH.

Patients / Materials and Methods: This is a retrospective and observational study that included 85 patients with AIH who received liver transplant at a reference center in Brazil, from 1996 to 2023. Demographic data was collected, and survival curves were performed using the Kaplan-Meier method.